Total Payments
$527,544
2024 Payments
$24,115
Companies
40
Transactions
357
Medicare Patients
17,817
Medicare Billing
$8.1M
Payment Breakdown by Category
Consulting$308,221 (58.4%)
Research$103,942 (19.7%)
Travel$88,151 (16.7%)
Other$17,046 (3.2%)
Food & Beverage$8,640 (1.6%)
Education$797.02 (0.2%)
Gifts$746.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $308,221 | 92 | 58.4% |
| Unspecified | $103,942 | 22 | 19.7% |
| Travel and Lodging | $88,151 | 104 | 16.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,046 | 6 | 3.2% |
| Food and Beverage | $8,640 | 112 | 1.6% |
| Education | $797.02 | 19 | 0.2% |
| Gift | $746.98 | 2 | 0.1% |
Payments by Type
General
$423,602
335 transactions
Research
$103,942
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $186,035 | 73 | $0 (2023) |
| Celgene Corporation | $110,460 | 40 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $39,022 | 20 | $0 (2017) |
| Sandoz Inc. | $28,289 | 12 | $0 (2021) |
| GENZYME CORPORATION | $23,862 | 18 | $0 (2024) |
| Amgen Inc. | $23,301 | 36 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $16,683 | 11 | $0 (2024) |
| Fresenius Kabi USA, LLC | $14,173 | 13 | $0 (2023) |
| Coherus Biosciences Inc. | $12,895 | 14 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $11,087 | 22 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,115 | 21 | Regeneron Pharmaceuticals, Inc. ($16,683) |
| 2023 | $5,303 | 23 | Genmab U.S., Inc. ($3,280) |
| 2022 | $51,707 | 25 | Takeda Pharmaceuticals U.S.A., Inc. ($35,704) |
| 2021 | $64,567 | 27 | Sandoz Inc. ($22,550) |
| 2020 | $61,653 | 39 | Takeda Pharmaceuticals U.S.A., Inc. ($29,856) |
| 2019 | $92,631 | 70 | Takeda Pharmaceuticals U.S.A., Inc. ($50,349) |
| 2018 | $126,918 | 90 | Takeda Pharmaceuticals U.S.A., Inc. ($56,540) |
| 2017 | $100,650 | 62 | Celgene Corporation ($43,470) |
All Payment Transactions
357 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $22.23 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $8,559.80 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,739.50 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,662.00 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $831.00 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $831.00 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $100.10 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $75.07 | General |
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $11.43 | General |
| 08/13/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $149.38 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Janssen Global Services, LLC | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $2,343.50 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Janssen Global Services, LLC | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $408.75 | General |
| Category: Oncology | ||||||
| 06/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $163.75 | General |
| 06/14/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $176.25 | General |
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $533.21 | General |
| 04/17/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $66.50 | General |
| Category: Oncology | ||||||
| 03/01/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $4,362.75 | General |
| Category: Oncology | ||||||
| 02/26/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Oncology | ||||||
| 01/16/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.45 | General |
| Category: Oncology | ||||||
| 12/20/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $120.19 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Oncology | ||||||
| 12/07/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $110.94 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-MM-036 - Connect MM- The Multiple Myeloma Disease Registry | Celgene Corporation | $18,300 | 1 |
| G-CSF UTILIZATION AND CLINICAL OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH G-CSF TREATMENT IN PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY IN A COMMUNITY ONCOLOGY SETTING | Sandoz Inc. | $16,000 | 1 |
| ACE-011-MDS-001 | Celgene Corporation | $14,836 | 2 |
| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $12,678 | 3 |
| CC-5013-MM-036 | Celgene Corporation | $10,807 | 1 |
| Connect MM- The Multiple Myeloma Disease Registry (CC-5013-MM-036) | Celgene Corporation | $10,166 | 1 |
| PNH Registry | Alexion Pharmaceuticals, Inc. | $8,516 | 2 |
| AZA-MDS-004 - A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDIN | Celgene Corporation | $6,310 | 1 |
| Prospective Observational Study of Onpro vs SOC. | Amgen Inc. | $2,025 | 1 |
| The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment of Multiple Myeloma INSIGHT | Takeda Pharmaceuticals U.S.A., Inc. | $1,567 | 3 |
| ACE-011-MDS-001 - An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-p | Celgene Corporation | $1,106 | 1 |
| ACE-011-MF-PI-0005 | Celgene Corporation | $578.00 | 1 |
| Incidence of Febrile Neutropenia (FN), Adherence and Compliance to Granulocyte Colony-Stimulating Factor (G-CSF) On-Body Injector (OBI) Versus Other FN Prophylaxis in Patients Receiving Myelosuppressive Chemotherapy: Subgroup Analysis in Breast Cance | Amgen Inc. | $343.65 | 1 |
| A multicenter, prospective, observational study to determine the incidence of febrile neutropenia ( | Amgen Inc. | $309.99 | 1 |
| A multicenter, prospective, observational study comparing the incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (Neulasta OBI) versus other FN prophylaxis in patients | Amgen Inc. | $213.31 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 77 | 4,628 | 92,413 | $12.7M | $3.3M |
| 2022 | 71 | 4,599 | 72,792 | $8.4M | $1.9M |
| 2021 | 76 | 4,407 | 66,290 | $6.5M | $1.6M |
| 2020 | 76 | 4,183 | 100,505 | $6.5M | $1.4M |
Total Patients
17,817
Total Services
332,000
Medicare Billing
$8.1M
Procedure Codes
305
All Medicare Procedures & Services
305 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie | Office | 2023 | 16 | 5,370 | $3.0M | $1.0M | 34.2% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 18,200 | $2.7M | $785,669 | 29.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 13 | 10,260 | $1.4M | $389,683 | 27.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 154 | 168 | $605,640 | $205,839 | 34.0% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 17 | 4,826 | $1.2M | $162,412 | 13.4% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 32 | 275 | $434,700 | $134,617 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 419 | 1,345 | $319,743 | $127,479 | 39.9% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 13 | 2,610 | $634,230 | $112,752 | 17.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 3,780 | $266,220 | $69,649 | 26.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 104 | 385 | $264,110 | $40,106 | 15.2% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 24 | 27 | $97,335 | $33,067 | 34.0% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 11 | 324 | $284,796 | $26,250 | 9.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 140 | $32,480 | $13,175 | 40.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 317 | 1,277 | $79,174 | $13,163 | 16.6% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 134 | 148 | $94,424 | $11,023 | 11.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 292 | 1,215 | $42,525 | $9,217 | 21.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 84 | 397 | $60,344 | $8,903 | 14.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 380 | 1,038 | $21,518 | $8,711 | 40.5% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 107 | 906 | $48,924 | $8,193 | 16.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 68 | 153 | $46,512 | $7,708 | 16.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 128 | $26,240 | $7,442 | 28.4% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 297 | 1,239 | $37,170 | $7,305 | 19.7% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 63 | 192 | $26,688 | $6,671 | 25.0% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 77 | 265 | $41,075 | $5,717 | 13.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 102 | $34,068 | $5,410 | 15.9% |
About Dr. Robert Rifkin, MD
Dr. Robert Rifkin, MD is a Hematology & Oncology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134103476.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Rifkin, MD has received a total of $527,544 in payments from pharmaceutical and medical device companies, with $24,115 received in 2024. These payments were reported across 357 transactions from 40 companies. The most common payment nature is "Consulting Fee" ($308,221).
As a Medicare-enrolled provider, Rifkin has provided services to 17,817 Medicare beneficiaries, totaling 332,000 services with total Medicare billing of $8.1M. Data is available for 4 years (2020–2023), covering 305 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Denver, CO
- Active Since 11/30/2005
- Last Updated 02/04/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1134103476
Products in Payments
- NINLARO (Drug) $102,617
- Revlimid (Drug) $39,378
- Sotatercept (Drug) $16,520
- ZARXIO (Drug) $16,000
- SARCLISA (Biological) $14,689
- Neulasta (Biological) $13,071
- Ninlaro (Drug) $12,678
- Udenyca (Biological) $9,520
- CD38 (Drug) $9,173
- SOLIRIS (Drug) $8,516
- CC-486 (Drug) $6,310
- ZYTIGA (Drug) $4,204
- XPOVIO (Drug) $3,457
- Epkinly (Drug) $3,280
- TECVAYLI (Biological) $2,752
- EXKIVITY (Drug) $2,750
- BRUKINSA (Drug) $1,906
- Stimufend (Biological) $1,530
- clonoSEQ (Device) $1,407
- DARZALEX (Biological) $1,375
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Dr. Yousuf Gaffar, Md, MD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Dr. Jeffrey Matous, Md, MD
Hematology & Oncology — Payments: $357,552
Hematology & Oncology $357,552
Dr. Peter Mcsweeney, Md, MD
Hematology & Oncology — Payments: $151,717
Hematology & Oncology $151,717
Dr. Moses Raj, Md, MD
Hematology & Oncology — Payments: $135,648
Hematology & Oncology $135,648
Dr. Tara Gregory, M.d, M.D
Hematology & Oncology — Payments: $135,068
Hematology & Oncology $135,068
Peter Forsberg, Md, MD
Hematology & Oncology — Payments: $98,100
Hematology & Oncology $98,100